Effects of Cerebrolysin on Language Ability in Non-fluent Aphasia Patients After Stroke: A Randomized, Placebo-controlled, Double-blinded, Single Center Study

PHASE4RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 12, 2025

Primary Completion Date

June 14, 2025

Study Completion Date

December 31, 2027

Conditions
Stroke
Interventions
DRUG

Cerebrolyisin

This intervention uses Cerebrolysin, which is a treatment aimed at improving language abilities and providing neuroprotection for patients with non-fluent aphasia following a stroke. Cerebrolysin is administered via intravenous injection, with the goal of improving language skills and promoting brain function recovery. The treatment is evaluated based on improvements in language abilities, neurological function recovery, and safety.

DRUG

Placebo

The placebo is administered alongside standard language therapy to the patients with non-fluent aphasia following a stroke. This allows for comparison with the Cerebrolysin group to assess the impact of the treatment on language abilities and neurological function recovery. The goal is to evaluate the improvements in language skills, neurological function recovery, and safety, comparing the effects between the active treatment and placebo.

Trial Locations (1)

Unknown

RECRUITING

Department and Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER